Free Trial

MBX Biosciences (MBX) Competitors

MBX Biosciences logo
$18.96 -1.04 (-5.20%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$19.29 +0.33 (+1.74%)
As of 09/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MBX vs. NTLA, EVO, SNDX, STOK, AMPH, RCUS, PHVS, TRML, GPCR, and DNTH

Should you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Intellia Therapeutics (NTLA), Evotec (EVO), Syndax Pharmaceuticals (SNDX), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Pharvaris (PHVS), Tourmaline Bio (TRML), Structure Therapeutics (GPCR), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry.

MBX Biosciences vs. Its Competitors

Intellia Therapeutics (NASDAQ:NTLA) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 52.2% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MBX Biosciences has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -908.48%. MBX Biosciences' return on equity of 0.00% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Intellia Therapeutics-908.48% -57.48% -45.04%
MBX Biosciences N/A N/A N/A

Intellia Therapeutics presently has a consensus price target of $27.39, suggesting a potential upside of 60.36%. MBX Biosciences has a consensus price target of $37.63, suggesting a potential upside of 98.44%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Intellia Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intellia Therapeutics
1 Sell rating(s)
7 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.53
MBX Biosciences
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00

MBX Biosciences has lower revenue, but higher earnings than Intellia Therapeutics. MBX Biosciences is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellia Therapeutics$57.88M31.68-$519.02M-$4.69-3.64
MBX BiosciencesN/AN/AN/A-$4.54-4.18

In the previous week, Intellia Therapeutics had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 18 mentions for Intellia Therapeutics and 14 mentions for MBX Biosciences. Intellia Therapeutics' average media sentiment score of 0.63 beat MBX Biosciences' score of 0.53 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Intellia Therapeutics
5 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MBX Biosciences
4 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

MBX Biosciences beats Intellia Therapeutics on 7 of the 13 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

MetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$636.94M$873.86M$5.76B$21.71B
Dividend YieldN/A4.84%5.53%3.52%
P/E Ratio-4.181.1976.4329.86
Price / SalesN/A114.73473.3162.12
Price / CashN/A17.6437.4624.72
Price / BookN/A6.4613.614.59
Net IncomeN/A-$5.56M$3.29B$1.00B
7 Day Performance90.74%0.53%1.87%0.64%
1 Month Performance32.31%5.75%4.03%2.77%
1 Year Performance-17.53%25.85%77.41%14.49%

MBX Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
MBX Biosciences
2.8873 of 5 stars
$18.96
-5.2%
$37.63
+98.4%
-14.9%$636.94MN/A-4.1836Trending News
Analyst Forecast
High Trading Volume
NTLA
Intellia Therapeutics
4.4552 of 5 stars
$12.43
+7.4%
$27.11
+118.2%
-20.4%$1.33B$52.86M-2.64600
EVO
Evotec
1.7469 of 5 stars
$3.68
+5.0%
$5.40
+46.9%
+12.2%$1.31B$777.33M0.004,827News Coverage
Gap Down
SNDX
Syndax Pharmaceuticals
3.8316 of 5 stars
$15.10
-4.7%
$39.22
+159.8%
-17.2%$1.30B$23.68M-3.89110Positive News
STOK
Stoke Therapeutics
3.5869 of 5 stars
$23.57
+0.7%
$25.57
+8.5%
+70.5%$1.29B$199.89M27.71100Positive News
AMPH
Amphastar Pharmaceuticals
4.1053 of 5 stars
$27.06
-0.8%
$31.60
+16.8%
-43.6%$1.26B$731.97M10.162,028Positive News
RCUS
Arcus Biosciences
1.9192 of 5 stars
$11.79
+1.8%
$21.14
+79.4%
-21.0%$1.25B$262M-3.72500Positive News
PHVS
Pharvaris
2.443 of 5 stars
$23.70
+1.4%
$34.00
+43.5%
+30.5%$1.24BN/A-7.0530
TRML
Tourmaline Bio
0.823 of 5 stars
$47.70
+0.1%
$45.65
-4.3%
+107.5%$1.23BN/A-13.9144
GPCR
Structure Therapeutics
3.2778 of 5 stars
$21.15
+4.7%
$75.71
+258.0%
-43.3%$1.22BN/A-20.14136
DNTH
Dianthus Therapeutics
2.7788 of 5 stars
$37.81
+2.1%
$61.57
+62.8%
+44.7%$1.22B$4.85M-11.6480

Related Companies and Tools


This page (NYSE:MBX) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners